Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of HORIZANT in Adolescents with RLS
NCT02633657Phase 1Withdrawn
- Sponsor
- XenoPort, Inc.
- Start
- Jan 2016
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of gabapentin enacarbil in restless legs syndrome (RLS), sponsored by XenoPort, Inc. Primary endpoints: Area under the concentration-time curve from the time of dosing to the last measurable concentration, Area under the concentration-time curve from the time of dosing extrapolated to infinity and 6 more. Planned start Jan 2016; status: withdrawn.
02
Drugs
gabapentin enacarbil
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT02633657.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02633657.